Multiparametric Prostate MRI
Prostate cancer is the most common cause of cancer in the adult male population. Early diagnosis is the most important factor for its treatment.
The new Multiparametric Prostate Magnetic Resonance Imaging System available in our laboratory (MP-MRI: MultiParametric MRI) is the most required additional examination together with the PSA haematology examination and urological assessment for the diagnosis of prostate cancer in case of suspicion and even before the transrectal biopsy.
Multiparametric MRI helps detect and map prostate cancer and ideally precedes prostate biopsy in order to further increase the accuracy of obtaining histological specimens, especially when the cancer site is small and cannot be palpated or when it is located on the anterior-ventricular surface of the prostate.
According to the guidelines of the British Urological Association, multiparametric MRI should precede any prostate biopsy.
With the new standard PI-RADS Version 2, we calculate the prostate’s imaging score which will help the urologist to choose the best treatment and follow-up for the patient.
- THEREFORE, WITH THE MRI
- Suspected areas that may conceal carcinogenesis may be identified
- The transrectal biopsies after the MRI are targeted in the tumor’s area and with greater chances of success
- The treatment of patients is planned with greater accuracy as the extent of the disease is imaged in detail
- The follow up and postoperative examination of patients is facilitated
What is the PI-RADS Version2 classification and where is it used?
PI-RADS (Prostate Imaging Reporting and Data System) is a classification of imaging findings of Prostate Magnetic Resonance imaging based on an international standard established and defined by the American College of Radiology (ACR) and now the upgraded version, VERSION 2, is used.
The purpose of PI-RADS is to create a common code of communication and information transfer from the Radiologist to our fellow Urologists to decide on appropriate treatment and follow-up of the patient.
PI-RADS evaluates multiple parameters of specialized Prostate MRI and establishes a risk score for suspected areas within the prostate gland on a 1 to 5 scale.
Benign focal points correspond to grade 1 and 2, partially malignant focal points to grade 3, and malignant focal points to grade 4 and 5. Thus, depending on your PI-RADS classification, your urologist will target the biopsy to the most dangerous areas or plan the required treatment.
- AMERICAN CANCER SOCIETY STATISTICS:
- The 1st commonly detected cancer in men
- The 2nd most common cancer-causing fatalities, after lung cancer
- Expected new cases per year in America of approximately 165,000
- Approximately 1 in 9 men in developed countries worldwide will be diagnosed with prostate cancer while due to its early prevention only 1 in 41 will be diagnosed at a very advanced stage
